{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:42:26Z","timestamp":1740170546393,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"DOI":"10.1007\/s40520-023-02569-7","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:02:48Z","timestamp":1697785368000},"page":"2471-2481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Importance of cytochrome 3A4 and 2D6-mediated drug\u2013drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0142-0210","authenticated-orcid":false,"given":"Th\u00e9odore","family":"Decaix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Royer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lapr\u00e9vote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Tritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Teillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Sellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"P\u00e9pin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"2569_CR1","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/jama.2019.5453","volume":"321","author":"SD Berry","year":"2019","unstructured":"Berry SD, Kiel DP, Col\u00f3n-Emeric C (2019) Hip Fractures in Older Adults in 2019. JAMA 321:2231\u20132232. https:\/\/doi.org\/10.1001\/jama.2019.5453","journal-title":"JAMA"},{"key":"2569_CR2","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.injury.2018.04.015","volume":"49","author":"N Veronese","year":"2018","unstructured":"Veronese N, Maggi S (2018) Epidemiology and social costs of hip fracture. Injury 49:1458\u20131460. https:\/\/doi.org\/10.1016\/j.injury.2018.04.015","journal-title":"Injury"},{"key":"2569_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/bmb\/ldv036","volume":"115","author":"MA Fernandez","year":"2015","unstructured":"Fernandez MA, Griffin XL, Costa ML (2015) Management of hip fracture. Br Med Bull 115:165\u2013172. https:\/\/doi.org\/10.1093\/bmb\/ldv036","journal-title":"Br Med Bull"},{"key":"2569_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/s12913-018-3523-x","volume":"18","author":"D Tedesco","year":"2018","unstructured":"Tedesco D, Gibertoni D, Rucci P et al (2018) Impact of rehabilitation on mortality and readmissions after surgery for hip fracture. BMC Health Serv Res 18:701. https:\/\/doi.org\/10.1186\/s12913-018-3523-x","journal-title":"BMC Health Serv Res"},{"key":"2569_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/jgs.13881","volume":"64","author":"DP Seitz","year":"2016","unstructured":"Seitz DP, Gill SS, Austin PC et al (2016) Rehabilitation of Older Adults with Dementia After Hip Fracture. J Am Geriatr Soc 64:47\u201354. https:\/\/doi.org\/10.1111\/jgs.13881","journal-title":"J Am Geriatr Soc"},{"key":"2569_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40266-017-0455-9","volume":"34","author":"LM Swart","year":"2017","unstructured":"Swart LM, van der Zanden V, Spies PE et al (2017) The Comparative Risk of Delirium with Different Opioids: A Systematic Review. Drugs Aging 34:437\u2013443. https:\/\/doi.org\/10.1007\/s40266-017-0455-9","journal-title":"Drugs Aging"},{"key":"2569_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/SLA.0b013e3181c1cfc9","volume":"251","author":"A Brouquet","year":"2010","unstructured":"Brouquet A, Cudennec T, Benoist S et al (2010) Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg 251:759\u2013765. https:\/\/doi.org\/10.1097\/SLA.0b013e3181c1cfc9","journal-title":"Ann Surg"},{"key":"2569_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2165\/11539430-000000000-00000","volume":"27","author":"RL Barkin","year":"2010","unstructured":"Barkin RL, Beckerman M, Blum SL et al (2010) Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 27:775\u2013789. https:\/\/doi.org\/10.2165\/11539430-000000000-00000","journal-title":"Drugs Aging"},{"key":"2569_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14656566.2019.1583743","volume":"20","author":"RA Gabriel","year":"2019","unstructured":"Gabriel RA, Swisher MW, Sztain JF et al (2019) State of the art opioid-sparing strategies for post-operative pain in adult surgical patients. Expert Opin Pharmacother 20:949\u2013961. https:\/\/doi.org\/10.1080\/14656566.2019.1583743","journal-title":"Expert Opin Pharmacother"},{"key":"2569_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1517\/14656566.2012.677823","volume":"13","author":"H Kokki","year":"2012","unstructured":"Kokki H, Kokki M, Sj\u00f6vall S (2012) Oxycodone for the treatment of postoperative pain. Expert Opin Pharmacother 13:1045\u20131058. https:\/\/doi.org\/10.1517\/14656566.2012.677823","journal-title":"Expert Opin Pharmacother"},{"key":"2569_CR11","unstructured":"International Narcotics Control Board, United Nations. Available online: https:\/\/www.incb.org\/incb\/en\/publications\/annual-reports\/annual-report-2020.html (accessed on 24 October 2022)."},{"key":"2569_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/FPC.0000000000000351","volume":"28","author":"R Huddart","year":"2018","unstructured":"Huddart R, Clarke M, Altman RB et al (2018) PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenet Genomics 28:230\u2013237. https:\/\/doi.org\/10.1097\/FPC.0000000000000351","journal-title":"Pharmacogenet Genomics"},{"key":"2569_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/bja\/aer395","volume":"108","author":"TI Saari","year":"2012","unstructured":"Saari TI, Ihmsen H, Neuvonen PJ et al (2012) Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth 108:491\u2013498. https:\/\/doi.org\/10.1093\/bja\/aer395","journal-title":"Br J Anaesth"},{"key":"2569_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/clpt.2008.64","volume":"84","author":"A Liukas","year":"2008","unstructured":"Liukas A, Kuusniemi K, Aantaa R et al (2008) Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 84:462\u2013467. https:\/\/doi.org\/10.1038\/clpt.2008.64","journal-title":"Clin Pharmacol Ther"},{"key":"2569_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/11586140-000000000-00000","volume":"28","author":"A Liukas","year":"2011","unstructured":"Liukas A, Kuusniemi K, Aantaa R et al (2011) Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging 28:41\u201350. https:\/\/doi.org\/10.2165\/11586140-000000000-00000","journal-title":"Drugs Aging"},{"key":"2569_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C et al (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461\u2013479. https:\/\/doi.org\/10.1016\/j.clpt.2006.01.009","journal-title":"Clin Pharmacol Ther"},{"key":"2569_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/dmd.32.4.447","volume":"32","author":"B Lalovic","year":"2004","unstructured":"Lalovic B, Phillips B, Risler LL et al (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447\u2013454. https:\/\/doi.org\/10.1124\/dmd.32.4.447","journal-title":"Drug Metab Dispos"},{"key":"2569_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpba.2016.09.024","volume":"144","author":"S Romand","year":"2017","unstructured":"Romand S, Spaggiari D, Marsousi N et al (2017) Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. J Pharm Biomed Anal 144:129\u2013137. https:\/\/doi.org\/10.1016\/j.jpba.2016.09.024","journal-title":"J Pharm Biomed Anal"},{"key":"2569_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/JCP.0b013e3182189892","volume":"31","author":"A Liukas","year":"2011","unstructured":"Liukas A, Hagelberg NM, Kuusniemi K et al (2011) Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol 31:302\u2013308. https:\/\/doi.org\/10.1097\/JCP.0b013e3182189892","journal-title":"J Clin Psychopharmacol"},{"key":"2569_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/0091270009336444","volume":"50","author":"J Gr\u00f6nlund","year":"2010","unstructured":"Gr\u00f6nlund J, Saari T, Hagelberg N et al (2010) Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 50:101\u2013108. https:\/\/doi.org\/10.1177\/0091270009336444","journal-title":"J Clin Pharmacol"},{"key":"2569_CR21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00228-010-0879-1","volume":"66","author":"TH Nieminen","year":"2010","unstructured":"Nieminen TH, Hagelberg NM, Saari TI et al (2010) Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir\/ritonavir. Eur J Clin Pharmacol 66:977\u2013985. https:\/\/doi.org\/10.1007\/s00228-010-0879-1","journal-title":"Eur J Clin Pharmacol"},{"key":"2569_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","volume":"65","author":"NM Hagelberg","year":"2009","unstructured":"Hagelberg NM, Nieminen TH, Saari TI et al (2009) Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65:263\u2013271. https:\/\/doi.org\/10.1007\/s00228-008-0568-5","journal-title":"Eur J Clin Pharmacol"},{"key":"2569_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00228-009-0775-8","volume":"66","author":"TI Saari","year":"2010","unstructured":"Saari TI, Gr\u00f6nlund J, Hagelberg NM et al (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 66:387\u2013397. https:\/\/doi.org\/10.1007\/s00228-009-0775-8","journal-title":"Eur J Clin Pharmacol"},{"key":"2569_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1097\/ALN.0b013e31819faa54","volume":"110","author":"TH Nieminen","year":"2009","unstructured":"Nieminen TH, Hagelberg NM, Saari TI et al (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110:1371\u20131378. https:\/\/doi.org\/10.1097\/ALN.0b013e31819faa54","journal-title":"Anesthesiology"},{"key":"2569_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.cca.2005.11.030","volume":"367","author":"HK Lee","year":"2006","unstructured":"Lee HK, Lewis LD, Tsongalis GJ et al (2006) Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367:196\u2013200. https:\/\/doi.org\/10.1016\/j.cca.2005.11.030","journal-title":"Clin Chim Acta"},{"key":"2569_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.12659\/AJCR.905637","volume":"18","author":"A Sakamoto","year":"2017","unstructured":"Sakamoto A, Yamashita M, Hori Y et al (2017) Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis. Am J Case Rep 18:1130\u20131134","journal-title":"Am J Case Rep"},{"key":"2569_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2125.2010.03653.x","volume":"70","author":"J Gr\u00f6nlund","year":"2010","unstructured":"Gr\u00f6nlund J, Saari TI, Hagelberg NM et al (2010) Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 70:78\u201387. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03653.x","journal-title":"Br J Clin Pharmacol"},{"key":"2569_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00228-010-0893-3","volume":"67","author":"O Kummer","year":"2011","unstructured":"Kummer O, Hammann F, Moser C et al (2011) Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 67:63\u201371. https:\/\/doi.org\/10.1007\/s00228-010-0893-3","journal-title":"Eur J Clin Pharmacol"},{"key":"2569_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/11539950-000000000-00000","volume":"31","author":"J Gr\u00f6nlund","year":"2011","unstructured":"Gr\u00f6nlund J, Saari TI, Hagelberg NM et al (2011) Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig 31:143\u2013153. https:\/\/doi.org\/10.2165\/11539950-000000000-00000","journal-title":"Clin Drug Investig"},{"key":"2569_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"key":"2569_CR31","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/jcph.1284","volume":"58","author":"J van den Anker","year":"2018","unstructured":"van den Anker J, Reed MD, Allegaert K et al (2018) Developmental Changes in Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol 58:S10\u2013S25. https:\/\/doi.org\/10.1002\/jcph.1284","journal-title":"J Clin Pharmacol"},{"key":"2569_CR32","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.3390\/ijms222312808","volume":"22","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M et al (2021) Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci 22:12808. https:\/\/doi.org\/10.3390\/ijms222312808","journal-title":"Int J Mol Sci"},{"key":"2569_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","volume":"13","author":"RL Maher","year":"2014","unstructured":"Maher RL, Hanlon J, Hajjar ER (2014) Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 13:57\u201365. https:\/\/doi.org\/10.1517\/14740338.2013.827660","journal-title":"Expert Opin Drug Saf"},{"key":"2569_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42:1289\u20131367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"key":"2569_CR35","unstructured":"Service de pharmacologie et toxicologie cliniques - H\u00f4pitaux universitaires de Gen\u00e8ve. Available online\u00a0: https:\/\/www.hug.ch\/sites\/interhug\/files\/structures\/pharmacologie_et_toxicologie_cliniques\/images\/carte_des_cytochromes_2020.pdf (accessed on 13 November 2022)."},{"key":"2569_CR36","unstructured":"Food and Drugs Administration. Available online: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers (accessed on 13 November 2022)."},{"key":"2569_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejim.2019.05.002","volume":"65","author":"P Gallo","year":"2019","unstructured":"Gallo P, De Vincentis A, Pedone C et al (2019) Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med 65:51\u201357. https:\/\/doi.org\/10.1016\/j.ejim.2019.05.002","journal-title":"Eur J Intern Med"},{"key":"2569_CR38","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S1474-4422(14)70103-6","volume":"13","author":"T Hadjistavropoulos","year":"2014","unstructured":"Hadjistavropoulos T, Herr K, Prkachin KM et al (2014) Pain assessment in elderly adults with dementia. Lancet Neurol 13:1216\u20131227. https:\/\/doi.org\/10.1016\/S1474-4422(14)70103-6","journal-title":"Lancet Neurol"},{"key":"2569_CR39","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/ALN.0000000000000671","volume":"122","author":"B Silbert","year":"2015","unstructured":"Silbert B, Evered L, Scott DA et al (2015) Preexisting cognitive impairment is associated with postoperative cognitive dysfunction after hip joint replacement surgery. Anesthesiology 122:1224\u20131234. https:\/\/doi.org\/10.1097\/ALN.0000000000000671","journal-title":"Anesthesiology"},{"key":"2569_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2106\/JBJS.18.00316","volume":"101","author":"FC Dolatowski","year":"2019","unstructured":"Dolatowski FC, Frihagen F, Bartels S et al (2019) Screw Fixation Versus Hemiarthroplasty for Nondisplaced Femoral Neck Fractures in Elderly Patients: A Multicenter Randomized Controlled Trial. J Bone Joint Surg Am 101:136\u2013144. https:\/\/doi.org\/10.2106\/JBJS.18.00316","journal-title":"J Bone Joint Surg Am"},{"key":"2569_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2151458513518343","volume":"4","author":"SA Strike","year":"2013","unstructured":"Strike SA, Sieber FE, Gottschalk A et al (2013) Role of fracture and repair type on pain and opioid use after hip fracture in the elderly. Geriatr Orthop Surg Rehabil 4:103\u2013108. https:\/\/doi.org\/10.1177\/2151458513518343","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"2569_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.arr.2010.06.001","volume":"9","author":"D Seripa","year":"2010","unstructured":"Seripa D, Pilotto A, Panza F et al (2010) Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev 9:457\u2013474. https:\/\/doi.org\/10.1016\/j.arr.2010.06.001","journal-title":"Ageing Res Rev"},{"key":"2569_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12893-016-0120-y","volume":"16","author":"MM Ghoneim","year":"2016","unstructured":"Ghoneim MM, O\u2019Hara MW (2016) Depression and postoperative complications: an overview. BMC Surg 16:5. https:\/\/doi.org\/10.1186\/s12893-016-0120-y","journal-title":"BMC Surg"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-023-02569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-023-02569-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-023-02569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T04:44:16Z","timestamp":1699332256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-023-02569-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2569"],"URL":"https:\/\/doi.org\/10.1007\/s40520-023-02569-7","relation":{},"ISSN":["1720-8319"],"issn-type":[{"type":"electronic","value":"1720-8319"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Paris-Saclay University (CER-Paris-Saclay-2022-047).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No subjects involved in this study objected to the retrospective processing of their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}